1
Paul Glue, David L Cutler, Melton B Affrime: Polyethylene glycol modified interferon therapy. Schering Corporation, Jaye P McLaughlin, June 1, 1999: US05908621 (91 worldwide citation)

A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.


2
Rumin Zhang, Philip W Mui, Patricia C Weber: Synthetic inhibitors of hepatitis C virus NS3 protease. Schering Corporation, Jaye P McLaughlin, November 23, 1999: US05990276 (89 worldwide citation)

An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the NS4A cofactor. In another embodiment the inh ...


3
Bruce A Malcolm, S Shane Taremi, Patricia C Weber, Nanhua Yao: Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide. Schering Corporation, Jaye P McLaughlin, Christine F Martin, April 3, 2001: US06211338 (26 worldwide citation)

Covalent HCV NS4A-NS3 complexes comprising the central hydrophobic domain of native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the linker to the amino terminus of the HCV NS3 protease domain.


4
Bimalendu Dasmahapatra, Nancy J Butkiewicz: Soluble active hepatitis C virus protease. Schering Corporation, Jaye P McLaughlin, December 1, 1998: US05843752 (25 worldwide citation)

Soluble covalent HCV NS3-NS4A complexes comprising the catalytic domain of native HICV NS3 protease fused to an HCV NS4A cofactor, wherein the cofactor has been modified to prevent cleavage by the HCV NS3 protease.


5
Bruce A Malcolm, S Shane Taremi, Patricia C Weber, Nanhua Yao: Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide. Schering Corporation, Thomas Triolo, Jaye P McLaughlin, November 25, 2003: US06653127 (18 worldwide citation)

Covalent HCV NS4A-NS3 complexes comprising the central hydrophobic domain of native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the linker to the amino terminus of the HCV NS3 protease domain.


6
Lata Ramanathan, Michele Wendel: Method for refolding insoluble aggregates of hepatitis C virus protease. Schering Corporation, Jaye P McLaughlin, Norman C Dulak, February 3, 1998: US05714371 (15 worldwide citation)

A method for solubulizing and refolding insoluble aggregates of HCV protease is presented. Insoluble aggregates of HCV NS3 protease are extracted from bacteria producing the aggregates. The aggregates of HCV NS3 are then solubilized in a buffer containing the denaturing reagent. Solubilized protease ...


7
Paul Reichert, Alan W Hruza, Nagamani Nagabushan, Tattanahalli Nagabhushan: Crystalline protein controlled release compositions. Schering Corporation, Jaye P McLaughlin, Norman C Dulak, December 21, 1999: US06004549 (14 worldwide citation)

A pharmaceutical composition comprised of a crystalline protein and polyethylene glycol or vegetable oil and a process for producing the same.


8
Ronald G Jubin: Assay for determining inhibitors of ATPase. Schering Corporation, Jaye P McLaughlin, Norman C Dulak, June 2, 1998: US05759795 (14 worldwide citation)

This invention provides materials and methods for identifying inhibitors of a Hepatitis C Virus NS3 protein ATPase. Methods for making and purifying such an ATPase are also provided by this invention.


9
Barbara Dalie, Xuedong Fan, Daniel Lundell, Charles A Lunn, Jimmy C Tan, Paul J Zavodny: Mammalian TNF-.alpha. convertases. Schering Corporation, Norman C Dulak, Jaye P McLaughlin, December 29, 1998: US05853977 (12 worldwide citation)

The present invention provides isolated human and bovine TNF-.alpha. convertases, nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provides antibodies and ...


10